Welcome to Larkspur Biosciences, where we are revolutionizing the field of biotechnology research to outsmart cancer. With an impressive $35.5M raised by Takeda Ventures, Inc., LS Polaris Innovation Fund, Cornell University, Med-Fine Capital, and 3E Bioventures Capital, and founded by visionary entrepreneur Catherine Sabatos-Peyton, Larkspur Biosciences is on a mission to build the next generation of precision immunotherapies. Despite the progress made in immunotherapy, many cancer patients still face unresponsive treatment options. At Larkspur, we target the unique ways that tumors manipulate the immune system, developing precision immunotherapies tailored to molecularly-defined patient populations. 

With a focus on the key intersection between the tumor and the immune system, our scientific foundation is rooted in groundbreaking discoveries by our founders. We are driven by a passion to solve complex problems and deliver new medicines to cancer patients with significant unmet needs. Leveraging our unique target discovery platform, LarkX, we harness patient genetics and immune phenotypes to fuel our pipeline and partnerships. By applying bioinformatics and advanced in vitro models, we can identify critical immune barriers and develop targeted solutions across multiple types of cancer.